Glioma- Neonc Technologies- NEO100-01

Written By Erica Stupfel

This study is to look at the safety and efficacy of NEO100 in recurrent or progressive Grade III or IV Gliomas with IDH1 Mutation.

Contact Information: 253-306-0532

Erica Stupfel

e*design Creative Services specializes in making professional design available to small companies and individuals. I understand the importance in brand identity and how a positive visual representation of your product or service can make the difference between success and failure. Your ideas and vision combined with my marketing and design expertise will be a sure success story.

https://www.edesigncreative.com
Previous

UW- Surveillance Colonoscopy Study for Colorectal Cancer
Next

The Hormone Receptor Positive HER2 Negative Clinical Stage II-III Breast Cancer (S2206)